40 results about "Nitric oxide synthetase" patented technology

Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and / or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors / antagonists of IL-1, inhibitors / antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors / antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and / or prophylactically active substance as defined above.

The invention discloses a making method of compound I and drug composition and application to treat tumour, which is 3-nitrile quinoline derivant (I) as dual-inhibitor protein kinase of tyrosine and nitric oxide synthase, wherein G1, G2, G3, G4, X, Z and n are defined as instruction.

The present invention relates to 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.

The invention discloses a kit for testing the genetic risk of hypertension. The kit comprises specific primer pairs for testing the single nucleotide polymorphic locus genotypes of an angiotensin converting enzyme gene (ACE), an angiotensin II receptor type1 gene (AGTR1) and an endothelial type nitric oxide synthase gene (NOS3) as well as specific fluorescent probe pairs, fluorescent quantitative PCR regular components, PCR reaction components and the like. The kit estimates the individual genetic risk of hypertension by synchronously testing the polymorphic locus genotypes of the genes closely related to the genetic risk of hypertension.

The invention discloses an anti-inflammatory effective component extract of antrodia cinnamomea sporocarp, a preparation method and application thereof. The preparation method comprises the following steps of: drying the antrodia cinnamomea sporocarp; and extracting the dried antrodia cinnamomea sporocarp by using ethanol, and collecting an ethanol extract to obtain the anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp. In order to achieve the better extraction effect, the method comprises the following steps of: concentrating the ethanol extract further; layering a concentration product by using water and ethyl acetate; and collecting an ethyl acetate extract to obtain the anti-inflammatory effective component extract. The anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp and Antrocamphin A separated from the antrodia cinnamomea sporocarp can reduce the expression of nitric oxide synthase or cycloxygenase 2 to inhibit pro-inflammation molecules from generating.

The invention provides the use of honokiol in the preparing process of anti tumor angiopoiesis medicine with a CAS number of 35354-74-6, the molecular weight being 266.33, the honokiol medicine comprises preparation allowed pharmaceutical excipient or carrier. The dosage form can be intestinal tract or non-intestinal tract combination, and the preparation can be made into liquid preparation, granule, tablet, electuary, capsule, drop pill or injection.

The present invention belongs to the field of research and development of medicines and health-care products, and provides new applications of NADH and / or NMN in preparing medicines and / or health-care products for prevention and treatment of male erectile dysfunctions. Administration of the NADH / NMN can activate nitric oxide synthase, thus stimulates a synthesis amount of nitric oxide, and has significant prevention and treatment effects on the male erectile dysfunctions caused by NO synthesis disorder.

The invention discloses a kit that is used for genetic risk detection of individual angiocardiopathy as well as health evaluation and management. The kit comprises an electrophoresis detecting primer pair that is used for detecting rs4646994 SNP polymorphism genotype on the gene of angiotonin converting enzyme (ACE), particularity primer pairs and particularity fluorescent probe pairs that are used for detecting rs5186 SNP locus on the gene of angiotonin II-1 type receptor (AGTR1), rs5443 SNP locus on the gene of G protein 3 subunit (GNB3) and rs1799983 SNP locus on the gene of endothelial nitric oxide synthase (NOS3), a fluorescent quantitative PCR routine component, and a PCR reaction component, etc. The kit of the invention implements cardiovascular health evaluation of detected person by evaluating the generic risk of developing angiocardiopathy and makes a health management plan that satisfies the genetic predisposition of detected person according to the four SNP locus genotypes that related with the genetic risk of developing angiocardiopathy of the detected person.

The invention discloses an application of inonotus obliquus polysaccharide used as a feed additive for litopenaeus vannamei, and the addition amount of the inonotus obliquus polysaccharide in a litopenaeus vannamei basal feed is 500-1500 mg / kg. The fact that the inonotus obliquus polysaccharide is used as the additive for the litopenaeus vannamei feed can substantially raise the weight gain rate and the specific growth rate of the litopenaeus vannamei, substantially reduce the feed coefficient, meanwhile substantially increase lysozyme and alkaline phosphatase in serum of the litopenaeus vannamei and raise total antioxidant capacity of the litopenaeus vannamei, increase nitric oxide synthetase and superoxide dismutase in the serum, and reduce the content of malonaldehyde in the serum. The inonotus obliquus polysaccharide has an equivalent action effect to beta glucan, and is a new-type immunopotentiator, and has a broad application prospect in the aquaculture field of the litopenaeus vannamei.

The invention provides a new application of Chinese caterpillar fungus. The Chinese caterpillar fungus has a new application in preparation of anti-inflammatory drugs, and further can be used for preparing drugs with neuroprotective effect to ischemic encephalopathy. The new application of Chinese caterpillar fungus is realized through lowering the levels of interleukin, tumour necrosis factor and intercellular adhesion molecules, and reducing the expression of nitric oxide synthase and cyclooxygenase by inhibiting the activity of transcription factor protein family NF-kB. The invention also provides a medicament composition which takes Chinese caterpillar fungus as the main component or one of the main components and is provided with therapeutic effect to ischemic encephalopathy.

The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.

Compounds and related compositions and methods as can be used to selectively inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.

A composition for preventing and / or treating piles contains at least one NO synthetase (NOS) inhibitor, especially iNOS inhibitor, at least one vascular angiogenesis inhibitor, especially VEGF inhibitor, and at least one matrix metal proteinase (MMP) inhibitor, especially MMP1, MMP3, MMP9 and / or MMP12 inhibitor.

The present invention relates to isolated nucleic acid molecules encoding nitric oxide synthases. The isolated nucleic acid molecules and their encoded protein or polypeptides are useful in methods for attaching a nitrogen group to a target moiety of a compound and for synthesizing a nitrogen-modified compound in a transgenic host cell. The present invention also relates to expression systems and host cells containing the nucleic acids of the present invention, as well as a method of recombinantly producing the nitric oxide synthases of the present invention.

This invention relates to methylaminopterin derivatives with 4-amino structure modified, which inhibit effect of nitrogen monoxide synthetase and growth of tumors. They have wide anti-cancer spectrum and little toxic side effect so as to be used in preparation of medicines for tumors, cancers, arthritis and intestinal diseases as well as chemicals for birth control.

The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by the Bacillus polyfermenticus KJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.

A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.

The present invention is directed to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein:R2 is selected from the group consisting of H and methyl; andR2 is selected from the group consisting of H and methyl.The compounds possess useful nitric oxide synthetase inhibiting activity, and are expected to be useful in the treatment or prophylaxis of a disease or condition in which the synthesis or over synthesis of nitric oxide forms a contributory part.

The invention relates to the fields of medicine and health, and discloses a novel application based on cortex magnoliae officinalis glycoside ingredient total glycoside, and the cortex magnoliae officinalis glycoside ingredient total glycoside is used to prepare products for improving a gastrointestinal function. Specifically, the inventors extract and separate the cortex magnoliae officinalis glycoside ingredient total glycoside through a natural medicinal chemistry method, and find that the cortex magnoliae officinalis glycoside ingredient total glycoside has the ability of regulating multiple gastrointestinal function-related indicators through pharmacological research, and the cortex magnoliae officinalis glycoside ingredient total glycoside has the ability of increasing the content ofmotilin and gastrin in serum and reducing the content of nitric oxide synthase, calcitonin gene-related peptide and vasoactive intestinal peptide in the serum, and 5-hydroxytryptamine in colon tissue, and can regulate the intestinal flora structure and reduce the content of short-chain fatty acids, so that the cortex magnoliae officinalis glycoside ingredient total glycoside has a good effect ofregulating the gastrointestinal function, and can be applied to the preparation and development of the products for improving the gastrointestinal function.

The invention provides a mouse inducible nitric oxide synthase gene which is transformed into a plant to improve the capability of drought resistance of the plant. The invention respectively uses two restriction endonucleases which are BamHI and SacI to digest the mouse inducible nitric oxide synthase gene with site-directed mutagenesis, has the digested mouse inducible nitric oxide synthase gene (muiNOS) connected with a pYPX 245 (AY178049) plant expression vector containing a double 35S promoter through T4DNA joinase, and acquires a recombinant plasmid pYPXmuiNOS containing the target gene muiNOS by digestion identification and sequence analysis. Finally, the mouse inducible nitric oxide synthase gene is transformed into the plant to acquire a transgenic plant with the capability of drought resistance.

The present invention relates to the field of medicinal chemistry, in particular to a class of 3-cyanoquinoline derivatives (I), a dual inhibitor of tyrosine protein kinase and nitric oxide synthase, wherein G1, G2, G3, G4, X, Z, See the specification for the definition of n. The invention also discloses a preparation method of compound I, a pharmaceutical composition containing it, and an application for treating tumor diseases.

The invention discloses a cascaded nano-enzyme as well as a preparation method and application thereof. The cascaded nano-enzyme comprises a metal organic framework carrier, nitric oxide synthetase combined with the metal organic framework carrier and platinum nanoparticles combined with the metal organic framework carrier. The cascaded nano-enzyme belongs to a nano size, has the natural advantage of passive accumulation in the liver compared with a small molecule drug, can increase the enrichment of the drug in the liver, and has higher targeting property. The platinum nanoparticles as the nano-enzyme have excellent reactive oxygen species (ROS) scavenging capacity and can catalyze the reactive oxygen to generate oxygen, the generated oxygen reacts with arginine under the catalysis of nitric oxide synthetase (iNOS) to generate NO in situ, and the bioavailability of NO is improved. Therefore, the cascaded nano-enzyme improves the targeting property and bioavailability of NO, and can simultaneously realize ROS scavenging and NO regulation, thereby realizing effective intervention on injury caused by liver ischemia reperfusion.

Peptide Nucleic Acid (PNA) antisense specific for inducible nitric oxide (iNOS) wherein the PNA compound is composed from nucleic acid sequence targeting iNOS, a peptide ligand which binds to a specific receptor, a positively charge moiety and an hydrophobic moiety. The invention also relates to the use of these compounds for the treatment of multiple sclerosis, neurodegenerative disorders, acute brain insults or other diseases where iNOS is involved.

A composition for preventing and / or treating piles contains at least one NO synthetase (NOS) inhibitor, especially iNOS inhibitor, at least one vascular angiogenesis inhibitor, especially VEGF inhibitor, and at least one matrix metal proteinase (MMP) inhibitor, especially MMP1, MMP3, MMP9 and / or MMP12 inhibitor.

The invention relates to a detection method of the ammonia (ammonia ion) content by enzymatic colorimetry and enzyme coupled reaction technology and composition and components of a reagent. The technology principle of the detection method is based on a series of catalytic reactions of ferredoxin-nitrite reductase, nitrite reductase and nitric oxide synthetase. The invention also relates to an ammonia (ammonia ion) diagnosis / detection kit. The detection method provided by the invention has advantages of high sensitivity and small error. Therefore, the detection method and the kit provided by the invention can be widely applied in clinical medicine / food inspection.

A process for testing the susceptibility of primary hypertension includes detecting if there are variations in hypophloeodal NO synthetase gene NOS, transcript and / or protein of an individual and determining its high susceptibility if there are. Its reagent kit is also disclosed.

The invention provides urechis unicinctus polypeptide with angiotensin converting enzyme inhibitory activity and application thereof. The urechis unicinctus polypeptide comprises a first polypeptide and / or a second polypeptide, wherein the amino acid sequence of the first polypeptide is as shown in SEQ ID NO. 1; and the amino acid sequence of the second polypeptide is as shown in SEQ ID NO. 2. Theurechis unicinctus polypeptide F2 and the urechis unicinctus polypeptide F7 have no inhibiting effect on proliferation of HUVEC cells, can antagonize the effect of noradrenaline (NE) on inhibiting NOrelease in the cells, and can inhibit the effect of promoting cell release ET-1 caused by the NE, so that the purpose of reducing blood pressure is achieved. According to the urechis unicinctus polypeptide, the activity of ACE is competitively inhibited, the content of bradykinin is increased, and the phosphorylation effect of endothelial nitric oxide synthase (eNOS) is influenced, so that the eNOS activity is improved, more NO is released, ET-1 is inhibited, and the effect of reducing blood pressure is achieved.

The invention provides a biological insecticide for control of brown rice planthopper. The biological insecticide comprises imidacloprid and water, and further comprises at least one of citrulline andarginine. The invention further provides a control method of brown rice planthopper, and the method includes the steps of: spraying the biological insecticide to rice plants, wherein the biological insecticide comprises imidacloprid and water, and at least one of citrulline and arginine. By adding exogenous arginine and citrulline, the activity of nitric oxide (NO) synthase in drug-resistant insects (brown rice planthopper) and the generation of nitric oxide can be increased, so that the activity of main detoxification cytochrome P450 is inhibited, and then the sensitivity of insects to imidacloprid is further increased.

The invention provides a biological insecticide for control of brown rice planthopper. The biological insecticide comprises imidacloprid and water, and further comprises at least one of citrulline andarginine. The invention further provides a control method of brown rice planthopper, and the method includes the steps of: spraying the biological insecticide to rice plants, wherein the biological insecticide comprises imidacloprid and water, and at least one of citrulline and arginine. By adding exogenous arginine and citrulline, the activity of nitric oxide (NO) synthase in drug-resistant insects (brown rice planthopper) and the generation of nitric oxide can be increased, so that the activity of main detoxification cytochrome P450 is inhibited, and then the sensitivity of insects to imidacloprid is further increased.

The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by the Bacillus polyfermenticus KJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.